Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents

PharmacoEconomics

Volumn 30, Issue 8, 2012, Pages

  Sikirica, Vanja ^a   Haim Erder, M ^a   Xie, Jipan ^b   MacAulay, Dendy ^b   Diener, Melissa ^b   Hodgkins, Paul ^a   Wu, Eric Q ^b  

^a SHIRE   (United States)

^b ANALYSIS GROUP   (United States)

Author keywords

Adolescents; Amfetamine; Attention deficit hyperactivity disorder; Children; Cost effectiveness; Cost utility; Guanfacine; Methylphenidate

Indexed keywords

AMPHETAMINE; DEXMETHYLPHENIDATE; GUANFACINE; LISDEXAMFETAMINE; METHYLPHENIDATE; PLACEBO; PSYCHOSTIMULANT AGENT;

ABDOMINAL PAIN; ADD ON THERAPY; ADJUVANT THERAPY; ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL ASSESSMENT; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECREASED APPETITE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; ECONOMIC EVALUATION; EVENING DOSAGE; FATIGUE; HEALTH CARE COST; HEALTH STATUS; HUMAN; INCREMENTAL COST EFFECTIVENESS RATIO; INSOMNIA; MAJOR CLINICAL STUDY; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; OPTIMAL DRUG DOSE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84863950604     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11632920-000000000-00000     Document Type: Article

References (41)

1. Olfson M, Gameroff MJ, Marcus SC, et al. National trends in the treatment of attention deficit/hyperactivity disorder. Am J Psychiatry 2003 Jun; 160 (6): 1071-7
2. Wolraich ML, Hannah JN, Pinnock TY, et al. Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. J Am Acad Child Adolesc Psychiatry 1996 Mar; 35 (3): 319-24
3. National Collaborating Centre for Mental Health. Attention deficit hyperactivity disorder: Diagnosis and management of ADHD in children, young people and adults [NICE clinical guideline no. 72]. Leicester: British Psychological Society, 2009 Mar
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. [text revision]. Washington, DC: American Psychiatric Association, 2000
5. Wehmeier PM, Schacht A, Barkley RA. Social and emotional impairment in children and adolescents with ADHD and the impact on quality of life. J Adolesc Health 2010 Mar; 46 (3): 209-17
6. Pelham WE, Foster EM, Robb JA. The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. J Pediatr Psychol 2007 Jul; 32 (6): 711-27
7. Birnbaum HG, Kessler RC, Lowe S, et al. Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin 2005; 20 (2): 195-205
8. Matza LS, Paramore C, Prasad M. A review of the economic burden of ADHD. Cost Eff Resour Alloc 2005; 3: 5
9. Hakkaart-van Roijen L, Zwirs BWC, Bouwmans C, et al. Societal costs and quality of life of children suffering from attention deficient hyperactivity disorder (ADHD). Eur Child Adolesc Psychiatry 2007; 16: 316-26
10. De Ridder A, De Graeve D. Healthcare use, social burden and costs of children with and without ADHD in Flanders, Belgium. Clin Drug Invest 2006; 26 (2): 75-90
11. Wehmeier PM, Schacht A, Rothenberger A. Change in the direct cost of treatment for children and adolescents with hyperkinetic disorder in Germany over a period of four years. Child Adolesc Psychiatry Ment Health 2009; 3 (1): 3
12. Gilmore A, Milne R. Methylphenidate in children with hyperactivity: review and cost-utility analysis. Pharmacoepidemiol Drug Saf 2001 Mar-Apr; 10 (2): 85-94
13. Adler LA, Reingold LS, Morrill MS, et al. Combination pharmacotherapy for adult ADHD. Curr Psychiatry Rep 2006; 8: 409-15
14. Pohl GM, Van Brunt DL, Ye W, et al. A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD). BMC Health Serv Res 2009; 9: 95
15. Shire Development LLC. Efficacy and safety of extendedrelease guanfacine hydrochloride in children and adolescents aged 6-17 years with attention-deficit/hyperactivity disorder (ADHD) [ClinicalTrials.gov identifier: NCT01244490]. Bethesda (MD): National Library of Medicine, 2012 [online]. Available from URL: http://clinicaltrials.gov/ct2/show/ NCT01244490 [Accessed 2012 Jun 18]
16. Shire Development LLC. Maintenance of efficacy of extended- release guanfacine HCl in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) [ClinicalTrials.gov identifier: NCT01081145]. Bethesda (MD): National Library of Medicine, 2012 [online]. Available from URL: http://clinicaltrials.gov/ct2/show/ NCT01081145 [Accessed 2012 Jun 18]
17. Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attentiondeficit/ hyperactivity disorder. Pediatrics 2008 Jan; 121 (1): e73-84
18. Spencer TJ, Greenbaum M, Ginsberg LD, et al. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009 Oct; 19 (5): 501-10
19. Sallee F, McGough J, Wigal T, et al., on behalf of the SPD503 Study Group. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: A placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009 Feb; 48 (2): 155-65
20. Intuniv- (guanfacine) extended-release tablets [package insert]. Wayne (PA): Shire US Inc., 2011 Feb
21. Wilens T, Bukstein O, Brams M, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2012; 51 (1): 74-85
22. King S, Griffin S, Hodges Z, et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Assess 2006; 10 (23): iii-iv, xiii-146
23. Prasad S, Arellano J, Steer C, et al. Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK. Int J Clin Pract 2009 Jul; 63 (7): 1031-40
24. Shire US Inc. A phase III, double-blind, randomized, placebocontrolled, multi-center, dose-optimization study evaluating the efficacy and safety of SPD503 in combination with psychostimulants in children and adolescents aged 6-17 years with a diagnosis of attention-deficit/hyperactivity disorder (ADHD). Shire US Inc., 2005. (Data on file)
25. Lord J, Paisley S. The clinical effectiveness and cost effectiveness of methylphenidate for hyperactivity in childhood [version 2]. London: National Institute for Clinical Excellence, 2000 Aug
26. Lloyd A, Hodgkins P, Sasane R, et al. Estimation of utilities in attention-deficit hyperactivity disorder for economic evaluations. Patient 2011; 4 (4): 247-57
27. Perwien A, Hall J, Swensen A, et al. Stimulant treatment patterns and compliance in children and adults with newly treated attention-deficit/ hyperactivity disorder. J Manag Care Pharm 2004; 10 (2): 122-9
28. U.S. Bureau of Labor Statistics. Consumer price index: CPI tables [online]. Available from URL: http://www.bls.gov/ cpi [Accessed 2012 Jun 18]
29. Guevara J, Lozano P, Wickizer T, et al. Utilization and cost of health care services for children with attention-deficit/ hyperactivity disorder. Pediatrics 2001 Jul; 108 (1): 71-8
30. Medi-Span-. Indianapolis (IN): Wolters Kluwer, 2011
31. Revicki D, Wood M. Patient-assigned health state utilities for depression-related outcomes: Differences by depression severity and antidepressant medications. J Affect Disord 1998 Feb; 48 (1): 25-36
32. Heeg B, Buskens E, Botteman M, et al. The costeffectiveness of atypicals in the UK. Value Health 2008 Dec; 11 (7): 1007-21
33. Botteman MF, Foley DJ, Ozminkowski RJ, et al. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: A decision analytical model. CNS Drugs 2007; 21 (4): 319-34
34. Kristiansen IS, Kvien TK, Nord E. Cost effectiveness of replacing diclofenac with a fixed combination of misoprostol and diclofenac in patients with rheumatoid arthritis. Arthritis Rheum 1999 Nov; 42 (11): 2293-302
35. Center for the Evaluation of Value and Risk in Health. The cost-effectiveness analysis registry. Boston (MA): Tufts Medical Center [online]. Available from URL: http:// www.cearegistry.org [Accessed 2012 Jun 18]
36. Bell C. The pursuit of transparency and quality improvement in cost-effectiveness analysis: A case study in diseasemodifying drugs for the treatment of multiple sclerosis. J Manag Care Pharm 2011; 17 (6): 463-8
37. Neumann PJ, Sandberg EA, Bell CM, et al. Are pharmaceuticals cost-effective? A review of the evidence. Health Affairs 2000; 19 (2): 92-109
38. Braithwaite RS, Meltzer DO, King JT, et al. What does the value of modern medicine say about the $50,000 per quality- adjusted life-year decision rule? Med Care 2008; 46: 349-56
39. Weinstein M. How much are Americans willing to pay for a quality-adjusted life year? Med Care 2008; 46 (4): 343-5
40. Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: Success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 2001 Feb; 40 (2): 168-79
41. Faber A, van Agthoven M, Kalverdijk LJ, et al. Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate- release methylphenidate: A study of cost effectiveness in the Netherlands. CNS Drugs 2008; 22 (2): 157-70